In a move set to reshape the landscape of clinical research technology, Thermo Fisher Scientific Inc. announced Wednesday that it will acquire Clario Holdings Inc. from a consortium led by Astorg, Nordic Capital, Novo Holdings, and Cinven for $8.875 billion in cash. The all-cash acquisition will deepen Thermo Fisher’s foothold in digital clinical trial solutions and expand its artificial intelligence-driven data capabilities.
A Strategic Merger of Science and Software
Clario, a global leader in endpoint data solutions for clinical trials, integrates digital tools to collect, manage, and analyze clinical evidence across every stage of drug development. The company’s platform accelerates how therapies are tested for safety, efficacy, and value—key steps in bringing new medicines to market.
Clario’s expertise spans electronic clinical outcome assessments, medical imaging, cardiac and respiratory monitoring, and wearable data analytics, serving biopharma giants and research organizations across the globe. With around 4,000 employees, Clario is projected to generate $1.25 billion in revenue in 2025.
